Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $2.2 million.

  • Nurix Therapeutics' Amortizatization of Intangibles fell 40.72% to $2.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $11.9 million, marking a year-over-year increase of 24.23%. This contributed to the annual value of $11.3 million for FY2024, which is 84.41% up from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Amortizatization of Intangibles is $2.2 million, which was down 18.66% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Amortizatization of Intangibles ranged from a high of $3.7 million in Q3 2024 and a low of $742,000 during Q1 2021.
  • In the last 3 years, Nurix Therapeutics' Amortizatization of Intangibles had a median value of $2.2 million in 2024 and averaged $2.4 million.
  • In the last 5 years, Nurix Therapeutics' Amortizatization of Intangibles skyrocketed by 9,375.00% in 2021 and then plummeted by 40.72% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Amortizatization of Intangibles stood at $853,000 in 2021, then spiked by 66.24% to $1.4 million in 2022, then climbed by 28.56% to $1.8 million in 2023, then soared by 91.61% to $3.5 million in 2024, then slumped by 40.72% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.7 million for Q2 2025, and $3.6 million during Q1 2025.